CHMP recommends approval of Omidria (ketorolac and phenylephrine) for cataract surgery- Omeros Corp
The EMA's Committee for Medicinal Products for Human Use has adopted a positive opinion for Omidria (phenylephrine and ketorolac injection) 1%/0.3%, from Omeros Corp, for use during cataract surgery and other intraocular lens (IOL) replacement procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and reduce postoperative eye pain.
No post-marketing follow-up studies or measures were recommended by CHMP for Omidria. The FDA has approved Omidria for use during cataract surgery or IOL replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins